The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715).
Zev A. Wainberg
Research Funding - Pfizer
Nicoletta Brega
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Craig Davis
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ashwin Gollerkeri
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Kristen J. Pierce
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Mie Suzuki
Employment or Leadership Position - Pfizer (B)
Rachelle Perea
Employment or Leadership Position - Pfizer